)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
OPKO Health (OPK) investor relations material
OPKO Health Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary29 Oct, 2025
Executive summary
Completed sale of BioReference oncology assets to Labcorp for $192.5M upfront and up to $32.5M in earnouts, streamlining operations and supporting share repurchases.
Recognized a $101.6M gain from the asset sale, with proceeds used to strengthen liquidity and fund buybacks.
Expanded stock repurchase program to $200M, with $73.8M spent as of September 30, 2025, and $126M–$126.2M remaining authorized.
Advanced pharmaceutical pipeline with four clinical candidates, new collaborations with Regeneron (potential $1B+ milestones) and Merck, and progress in ModeX and Merck clinical programs.
Maintained strong cash position of $428.9M at quarter-end, supported by asset sales and investment proceeds.
Financial highlights
Q3 2025 total revenue was $151.7M, down 13% year-over-year, with diagnostics revenue at $95.2M (including $19.5M from sold assets) and pharmaceutical revenue at $56.4M.
Q3 2025 operating income was $48.1M, up from $14.2M in Q3 2024, driven by the gain on asset sale.
Q3 2025 net income was $21.6M ($0.03/share), compared to $24.9M ($0.04/share) in Q3 2024.
Gross margin improved due to cost reductions and asset sales.
Cash, cash equivalents, and restricted cash totaled $428.9M as of September 30, 2025.
Outlook and guidance
Q4 2025 revenue expected at $135M–$140M; service revenue $70M–$75M, product revenue $40M–$45M, other revenue $25M–$30M.
Q4 2025 costs and expenses expected at $175M–$180M; R&D $30M–$35M; D&A $24M.
2026: BioReference to be profitable with low single-digit revenue growth; pharmaceutical business to grow mid-single digits and improve operating income by low double digits.
Ngenla profit share payments expected at $32M–$35M in 2026.
Up to $100M planned R&D investment in 2026, with up to six phase I programs enrolling.
MDX2001 Phase Ib expansion patient selection criteria
Regeneron collaboration: indications and programs
4Kscore growth drivers and future contribution
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next OPKO Health earnings date
Q4 202527 Feb, 2026
Next OPKO Health earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
OPKO Health, Inc., together with its subsidiaries, provides diagnostic and pharmaceutical products to patients in the United States and internationally. The company offers clinical laboratory diagnostic services under the Diagnostic Systems Laboratories (DSL) brand name. It also develops and commercializes pharmaceutical products for oncology, cardiovascular disease, hospital intensive care, gout and metabolic disorders, reproductive health and urology; as well as complementary dietary supplement products for women’s health, eye care and mineral deficiencies. In addition, it engages in the research and development of proprietary medical imaging contrast agents for use in cardiac electrophysiological procedures; along with advanced personalized genetic diagnostics technology using microfluidics extracted from blood samples to help identify genetic markers associated with disease onset or progression; as well as biomarkers associated with efficacy that are useful in assessing treatment options
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage